Study guide

8.1 Congenital Heart Defects & Ductal-Dependent Lesions

Board Certified Pediatric Pharmacy Specialist BCPPS

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Pediatric Patient Characteristics — Growth, Anthropometrics & Perinatal Exposure

1.1 Normal Growth, Development & Growth-Chart Interpretation 1.2 Anthropometrics: Body Surface Area, Dosing Weights & Maximum-Dose Caps 1.3 Medication Use in Pregnancy and Lactation

2 Chapter 2: Developmental Pharmacokinetics & Neonatal Principles

2.1 Developmental PK: Absorption, Distribution & Body Water Dynamics 2.2 Hepatic Metabolism & CYP/UGT Isoenzyme Maturation 2.3 Renal Function Maturation & Glomerular Filtration Development

3 Chapter 3: Neonatal Critical Care & Prematurity Complications

3.1 Neonatal Sepsis & Meningitis (Early-Onset vs Late-Onset Sepsis) 3.2 Respiratory Distress Syndrome, Surfactant & Bronchopulmonary Dysplasia 3.3 Patent Ductus Arteriosus, Apnea of Prematurity & Necrotizing Enterocolitis

4 Chapter 4: Pediatric Infectious Diseases — Respiratory & ENT Infections

4.1 Acute Otitis Media, Sinusitis & Pharyngitis 4.2 Pediatric Community-Acquired Pneumonia & Parapneumonic Effusion 4.3 Bronchiolitis, RSV Prevention (Nirsevimab, Clesrovimab, Palivizumab) & Viral Lower Respiratory Infections

5 Chapter 5: Pediatric Infectious Diseases — Systemic, Bone & CNS Infections

5.1 Pediatric Meningitis, Encephalitis & Brain Abscess 5.2 Skin, Soft Tissue, Osteomyelitis & Septic Arthritis 5.3 Pediatric Sepsis, Febrile Neutropenia & Central Line-Associated Bloodstream Infections

6 Chapter 6: Pediatric Pulmonary Medicine — Asthma & Status Asthmaticus

6.1 Chronic Pediatric Asthma Assessment & Stepwise Outpatient Pharmacotherapy 6.2 Status Asthmaticus & Acute Exacerbation Pharmacotherapy in ED/PICU 6.3 Aerosol Drug Delivery, Spacers & Specialized Inhalation Devices

7 Chapter 7: Cystic Fibrosis & Chronic Pediatric Respiratory Disorders

7.1 Pathophysiology, Diagnosis & Airway Clearance in Cystic Fibrosis 7.2 CFTR Modulator Therapies & Monitoring 7.3 CF Pulmonary Exacerbations, Chronic Infection Management & Comorbidities

8 Chapter 8: Pediatric Cardiology & Hemodynamics

8.1 Congenital Heart Defects & Ductal-Dependent Lesions 8.2 Pediatric Heart Failure & Cardiomyopathies 8.3 Pediatric Arrhythmias & Syncope Management

9 Chapter 9: Pediatric Resuscitation, Shock & Critical Care Support

9.1 PALS Resuscitation Algorithms & Cardiac Arrest Pharmacotherapy 9.2 Pediatric Shock States & Vasoactive / Inotropic Selection 9.3 Extracorporeal Membrane Oxygenation (ECMO) & Critical Care PK

10 Chapter 10: Pediatric Neurology & Psychiatric Disorders

10.1 Neonatal Seizures & Pediatric Status Epilepticus 10.2 Pediatric Epilepsy Syndromes & Maintenance Anticonvulsants 10.3 Attention-Deficit/Hyperactivity Disorder (ADHD) & Pediatric Mood Disorders

11 Chapter 11: Pediatric Endocrinology & Metabolic Disorders

11.1 Pediatric Type 1 Diabetes Mellitus Management & Insulin Technologies 11.2 Diabetic Ketoacidosis (DKA) Protocols & Cerebral Edema Prevention 11.3 Growth Hormone, Pubertal Disorders & Congenital Adrenal Hyperplasia

12 Chapter 12: Pediatric Hematology, Oncology & Supportive Care

12.1 Sickle Cell Disease: Vaso-occlusive Crises & Disease-Modifying Therapies 12.2 Pediatric Acute Lymphoblastic Leukemia (ALL) & Chemotherapy Toxicities 12.3 Oncologic Emergencies: Tumor Lysis Syndrome & Supportive Care

13 Chapter 13: Pediatric Medication Safety & Error Prevention

13.1 High-Alert Pediatric Medications & Ten-Fold Dosing Calculation Traps 13.2 Smart Infusion Pumps & Dose Error Reduction Systems (DERS) 13.3 Medication Reconciliation & Pediatric Care Transitions

14 Chapter 14: Pediatric Compounding & Formulation Technology

14.1 Non-Sterile Compounding (USP <795>) & Liquid Formulations 14.2 Sterile Compounding (USP <797>) & Micro-Dosing Considerations 14.3 Hazardous Drug Handling (USP <800>) & Excipient Toxicities

15 Chapter 15: Fluids, Electrolytes & Clinical Nutrition Support

15.1 Fluid Requirements, Dehydration Assessment & Maintenance Therapy 15.2 Electrolyte Disturbances: Sodium, Potassium & Calcium Management 15.3 Pediatric & Neonatal Parenteral Nutrition (PN) Formulation

16 Chapter 16: Pediatric Pain Management, Sedation & Delirium

16.1 Age-Specific Pain Assessment Tools & Analgesic Selection 16.2 Procedural Sedation & Rapid Sequence Intubation in Children 16.3 PICU Delirium, Iatrogenic Withdrawal & Weaning Strategies

17 Chapter 17: Biostatistics & Study Design in Pediatric Research

17.1 Observational vs Experimental Pediatric Study Designs 17.2 Biostatistical Testing, Power & Sample Size in Small Pediatric Cohorts 17.3 Diagnostic Testing, Sensitivity, Specificity & Predictive Values

18 Chapter 18: Pediatric Evidence Appraisal, Regulatory Framework & Ethics

18.1 Pediatric Drug Legislation: BPCA, PREA & Labeling Nuances 18.2 Institutional Review Boards (IRB), Assent & Informed Consent in Minors 18.3 Evaluating Clinical Practice Guidelines & Formulating Off-Label Recommendations

19 Chapter 19: Pediatric Education, Health Literacy & Communication

19.1 Caregiver Health Literacy & Pediatric Medication Adherence 19.2 Interprofessional Education & Clinical Teaching Strategies 19.3 Developing Age-Appropriate Patient Educational Materials

20 Chapter 20: Pediatric Immunizations & Public Health Advocacy

20.1 ACIP Pediatric Immunization Schedule: Routine Childhood Vaccines 20.2 Adolescent Immunizations, Vaccine Hesitancy & Catch-Up Schedules 20.3 Pediatric Public Health Disparities & Special Population Advocacy

21 Chapter 21: Pediatric Practice Management — Laboratory Stewardship, Pharmacoeconomics & Informatics

21.1 Pediatric Laboratory Practices: Blood Conservation, Sampling Timing & Age-Specific Reference Intervals 21.2 Pharmacoeconomics, Formulary Management & Cost-Containment in Pediatrics 21.3 Clinical Informatics, CPOE Decision Support & Drug Shortage Management

8.1 Congenital Heart Defects & Ductal-Dependent Lesions

Key Takeaways Explain This Topic AI

Congenital heart defects (CHDs) are categorized hemodynamically into ductal-dependent pulmonary blood flow, ductal-dependent systemic blood flow, and parallel circulation; closure of the patent ductus arteriosus (PDA) within 24 to 72 hours of life precipitates hypoxemia, cardiovascular collapse, or profound cyanosis depending on the lesion.

Ductal-dependent pulmonary lesions (pulmonary atresia, critical pulmonary stenosis, tricuspid atresia, Tetralogy of Fallot with severe PS) present with refractory cyanosis (PaO2 < 50 mmHg failing the hyperoxia test), whereas ductal-dependent systemic lesions (HLHS, interrupted aortic arch, critical aortic stenosis, critical coarctation) present with cardiogenic shock, diminished femoral pulses, and severe lactic acidosis.

Alprostadil (Prostaglandin E1 / PGE1) continuous IV infusion is life-saving, initiated at 0.05–0.1 mcg/kg/min and rapidly titrated downward to maintenance of 0.01–0.025 mcg/kg/min once ductal patency is confirmed; drug-induced apnea occurs in 10%–12% of neonates (especially <2 kg), mandating immediate bedside intubation readiness.

Prolonged alprostadil infusions (>120 hours to several weeks) cause cortical hyperostosis of long bones, cutaneous flushing, fever (hyperpyrexia), and gastric outlet obstruction via antral foveolar hyperplasia.

Single-ventricle staged surgical palliation proceeds through Stage 1 (Norwood with modified Blalock-Taussig or Sano shunt at 1–2 weeks), Stage 2 (bidirectional Glenn at 4–6 months), and Stage 3 (Fontan completion at 2–4 years); interstage Stage 1 requires low-dose aspirin (1–5 mg/kg/day) to prevent catastrophic shunt thrombosis.

Last updated: September 2026

8.1 Congenital Heart Defects & Ductal-Dependent Lesions

Congenital heart defects (CHDs) represent the most prevalent class of congenital anatomical anomalies, occurring in approximately 8 to 10 per 1,000 live births . In the fetal circulation, gas exchange occurs within the placenta, and high pulmonary vascular resistance (PVR) shunts approximately 90% of right ventricular cardiac output away from non-ventilated lungs through the ductus arteriosus directly into the descending aorta. At delivery, lung expansion and umbilical cord clamping trigger an abrupt fall in PVR and a dramatic rise in systemic vascular resistance (SVR). Concurrently, circulating levels of maternal and placental prostaglandin E2 ( P G E 2 PGE_2 PG E 2 ​ ) drop precipitously as the infant's pulmonary vasculature metabolizes circulating eicosanoids. In healthy neonates, exposure to elevated arterial oxygen tension ( P a O 2 > 50 – 60 mmHg PaO_2 > 50\text{--}60\text{ mmHg} P a O 2 ​ > 50 – 60 mmHg ) induces smooth muscle contraction and functional ductal closure within 12 to 24 hours , followed by permanent anatomical obliteration (ligamentum arteriosum) over 2 to 3 weeks.

However, in critical congenital heart disease, postnatal ductal closure disrupts vital blood flow paths, precipitating profound hypoxemia, cardiovascular collapse, or death unless patency of the ductus arteriosus is pharmacologically maintained.

Classification of Congenital Heart Defects

Congenital heart defects are traditionally classified by the presence or absence of cyanosis and further categorized by underlying hemodynamics. ┌──────────────────────────────────────────────┐

  • │ Congenital Heart Defects │
  • └──────────────────────┬───────────────────────┘
  • │
  • ┌─────────────────────────┴────────────────────────┐
  • ▼ ▼
  • ┌───────────────────────────┐ ┌───────────────────────────┐
  • │ Acyanotic Lesions │ │ Cyanotic Lesions │
  • │ (Left-to-Right Shunts │ │ (Right-to-Left Shunts │
  • │ & Acyanotic Obstruct) │ │ & Transposition) │
  • └─────────────┬─────────────┘ └─────────────┬─────────────┘
  • │ │
  • Ventricular Septal Defect (VSD) • Tetralogy of Fallot (TOF)
  • Atrial Septal Defect (ASD) • Transposition of Great Arteries (TGA)
  • Patent Ductus Arteriosus (PDA) • Tricuspid Atresia (TA)
  • Atrioventricular Septal Defect (AVSD) • Truncus Arteriosus
  • Coarctation of the Aorta (mild) • Total Anomalous Pulm Venous Return
  • Pulmonic / Aortic Stenosis (mild) • Hypoplastic Left Heart Syndrome (HLHS)
  • The Hyperoxia Test

When a newborn presents with central cyanosis, distinguishing cyanotic CHD from primary pulmonary parenchymal disease (e.g., respiratory distress syndrome, meconium aspiration syndrome, persistent pulmonary hypertension of the newborn [PPHN]) is critical. The hyperoxia test evaluates arterial blood gas response to 100% fraction of inspired oxygen ( F i O 2 FiO_2 F i O 2 ​ ) administered for 10 to 15 minutes:

Pulmonary Parenchymal Disease: Alveolar ventilation-perfusion ( V / Q V/Q V / Q ) mismatch or diffusion limitation is partially or fully overcome by 100% oxygen, driving P a O 2 PaO_2 P a O 2 ​ above 150 to 300 mmHg 150\text{ to } 300\text{ mmHg} 150 to 300 mmHg .

Cyanotic Congenital Heart Defect: Due to a fixed anatomical right-to-left intracardiac or extracardiac shunt, deoxygenated systemic venous blood bypasses the pulmonary bed entirely. The P a O 2 PaO_2 P a O 2 ​ remains severely depressed—typically < 100 mmHg < 100\text{ mmHg} < 100 mmHg (and frequently < 50 to 60 mmHg < 50\text{ to } 60\text{ mmHg} < 50 to 60 mmHg ) with minimal or no rise in pulse oximetry saturation ( S p O 2 SpO_2 Sp O 2 ​ ).

Ductal-Dependent Lesions: Hemodynamic Taxonomy

Ductal-dependent cardiac lesions represent true pediatric emergencies. They are categorized into three distinct pathophysiological groups based on the vascular circuit sustained by the patent ductus arteriosus.

1. Ductal-Dependent Pulmonary Blood Flow

In these lesions, anatomical obstruction of the right ventricular outflow tract prevents systemic venous blood from reaching the pulmonary capillary bed via the pulmonary valve. Blood reaches the lungs solely via left-to-right flow through the ductus arteriosus (aorta → \rightarrow → pulmonary artery).

Key Anatomical Lesions:

  • Pulmonary Atresia (with intact ventricular septum or with VSD)
  • Critical Pulmonary Valve Stenosis
  • Tricuspid Atresia
  • Severe Tetralogy of Fallot (with severe infundibular or valvular pulmonary stenosis)
  • Ebstein Anomaly (severe form with functional pulmonary atresia)

Clinical Presentation: As the ductus constricts within the first hours to days of life, pulmonary perfusion drops precipitously. The infant manifests profound, progressive cyanosis refractory to supplemental oxygen , tachypnea without prominent retractions, metabolic acidosis, and rapid hypoxemic arrest.

Therapeutic Goal: Re-open and maintain ductal patency to restore pulmonary blood flow and normalize systemic arterial oxygen delivery.

2. Ductal-Dependent Systemic Blood Flow

In these lesions, severe left ventricular outflow tract obstruction prevents oxygenated blood from leaving the left ventricle to supply the systemic arterial circulation. Systemic perfusion is maintained entirely via right-to-left flow through the ductus arteriosus (pulmonary artery → \rightarrow → descending aorta → \rightarrow → systemic vascular beds).

Key Anatomical Lesions:

Hypoplastic Left Heart Syndrome (HLHS): Marked hypoplasia of the left ventricle, mitral valve, aortic valve, and ascending aorta.

  • Critical Aortic Valve Stenosis
  • Interrupted Aortic Arch (IAA)
  • Severe / Critical Coarctation of the Aorta

Clinical Presentation: In utero and immediately post-birth, the infant appears deceptively well. As the PDA constricts at 24 to 72 hours, systemic cardiac output collapses. The infant presents with pallor, mottled cool extremities, weak or absent femoral pulses, prolonged capillary refill (>4 seconds), oliguria/anuria, severe metabolic lactic acidosis , and rapid progression to cardiogenic shock.

Therapeutic Goal: Maintain ductal patency to sustain systemic perfusion; balance systemic and pulmonary vascular resistances ( Q p : Q s ≈ 1 : 1 Q_p:Q_s \approx 1:1 Q p ​ : Q s ​ ≈ 1 : 1 ) to avoid pulmonary overcirculation and systemic steal.

3. Parallel Circulations (D-Transposition of the Great Arteries)

In D-Transposition of the Great Arteries (D-TGA) , ventriculoarterial discordance exists: the aorta arises from the morphologic right ventricle, and the pulmonary artery arises from the morphologic left ventricle. This configuration creates two separate, parallel, closed circulatory loops:

Systemic loop: Systemic veins → \rightarrow → Right atrium → \rightarrow → Right ventricle → \rightarrow → Aorta → \rightarrow → Body → \rightarrow → Systemic veins (deoxygenated blood recirculates).

Pulmonary loop: Pulmonary veins → \rightarrow → Left atrium → \rightarrow → Left ventricle → \rightarrow → Pulmonary artery → \rightarrow → Lungs → \rightarrow → Pulmonary veins (oxygenated blood recirculates).

Survival is entirely impossible without bidirectional mixing sites: an atrial septal defect (ASD/PFO) , a ventricular septal defect (VSD) , or a patent ductus arteriosus (PDA) . PGE1 infusion maintains ductal patency, expanding intracardiac mixing. If mixing across the atrial septum is restrictive, emergent bedside balloon atrial septostomy (Rashkind procedure) is mandatory.

Lesion Category Typical Cardiac Defect Examples Direction of Ductal Shunt Clinical Presentation upon Ductal Closure Immediate Pharmacotherapy Goal

Ductal-Dependent Pulmonary Blood Flow Pulmonary atresia, critical pulmonary stenosis, tricuspid atresia, Tetralogy of Fallot with severe PS Left-to-right (Aorta → \rightarrow → Pulmonary Artery) Severe, progressive central cyanosis ( S p O 2 < 70 % SpO_2 < 70\% Sp O 2 ​ < 70% ), hypoxemia unresponsive to 100% F i O 2 FiO_2 F i O 2 ​ , tachypnea Re-establish pulmonary perfusion; titrate PGE1 to target S p O 2 SpO_2 Sp O 2 ​ 75–85%

Ductal-Dependent Systemic Blood Flow Hypoplastic left heart syndrome (HLHS), critical aortic stenosis, interrupted aortic arch, critical coarctation Right-to-left (Pulmonary Artery → \rightarrow → Descending Aorta) Cardiogenic shock, absent femoral pulses, gray pallor, oliguria, profound lactic acidosis ( p H < 7.15 pH < 7.15 p H < 7.15 , lactate > 5 mmol/L > 5\text{ mmol/L} > 5 mmol/L ) Re-establish systemic output; balance Q p : Q s Q_p:Q_s Q p ​ : Q s ​ ; avoid hyperoxia-induced pulmonary vasodilation

Parallel Circulation D-Transposition of the Great Arteries (D-TGA) Bidirectional (depends on phase of cardiac cycle) Severe cyanosis, profound hypoxemia ( S p O 2 < 60 % SpO_2 < 60\% Sp O 2 ​ < 60% ) with adequate or increased pulmonary blood flow Maintain ductal patency to facilitate inter-circulatory blood mixing; prepare for balloon atrial septostomy

Prostaglandin E1 (Alprostadil / PGE1) Pharmacology & Therapeutics

Alprostadil (synthetic Prostaglandin E1) is the cornerstone medical countermeasure for ductal-dependent congenital heart defects.

Mechanism of Action & Hemodynamic Dynamics

Alprostadil binds directly to E P 4 EP_4 E P 4 ​ prostanoid receptors on the vascular smooth muscle of the ductus arteriosus. Receptor activation stimulates membrane-bound adenylyl cyclase, driving an intracellular accumulation of cyclic adenosine monophosphate ( cAMP ). Elevated cAMP reduces intracellular free calcium concentration, causing profound relaxation and dilation of the ductal smooth muscle.

Response Timing: In a closed or severely constricted ductus, smooth muscle relaxation begins within 10 to 30 minutes of initiating IV infusion. Arterial oxygen tension increases by 15 to 30 mmHg in pulmonary lesions, while systemic arterial pressure and femoral pulses normalize in systemic lesions.

Responsiveness Window: Ductal smooth muscle is highly responsive to PGE1 in neonates < 7 to 14 days of age < 7\text{ to } 14\text{ days of age} < 7 to 14 days of age . Beyond 2 to 3 weeks of life, anatomical remodeling (fibrosis, subendothelial intimal proliferation) limits pharmacologic dilation, although trials of high-dose PGE1 remain clinically indicated during emergencies.

Dosing Protocols & Administration

Initial Opening Dose: 0.05 to 0.1 mcg/kg/min 0.05\text{ to }0.1\text{ mcg/kg/min} 0.05 to 0.1 mcg/kg/min continuous intravenous infusion.

Rapid Down-Titration (Maintenance Dose): As soon as ductal patency is established—demonstrated by improved S p O 2 SpO_2 Sp O 2 ​ (75%–85% in pulmonary lesions), palpable femoral pulses, base deficit normalization, and echocardiographic confirmation—the infusion must be rapidly titrated downward to 0.01 to 0.025 mcg/kg/min 0.01\text{ to }0.025\text{ mcg/kg/min} 0.01 to 0.025 mcg/kg/min .

Refractory Cases: If initial response is absent after 15 to 30 minutes, the infusion may be transiently escalated to 0.2 mcg/kg/min 0.2\text{ mcg/kg/min} 0.2 mcg/kg/min while preparing for urgent catheter-based or surgical intervention. PGE1 Infusion Protocol Architecture

  • [Suspected Ductal-Dependent Lesion]
  • │
  • ▼
  • [Initiate PGE1 at 0.05 - 0.1 mcg/kg/min IV Continuous Infusion]
  • │
  • ├─────────────────────────────────────────┐
  • ▼ ▼
  • [Clinical Response within 15-30 min] [No Response after 15-30 min]
  • SpO2 75-85% (pulmonary lesions) • Increase dose to 0.2 mcg/kg/min
  • Femoral pulses palpable (systemic) • Confirm line patency & IV site
  • Lactate clearing, urine >1 mL/kg/h • Urgent echocardiogram / catheterization
  • │
  • ▼
  • [Titrate Down to Maintenance: 0.01 - 0.025 mcg/kg/min]
  • Minimizes dose-dependent adverse effects (apnea, hypotension, fever)
  • Maintain continuous infusion until definitive surgical/catheter palliation
  • Pharmacokinetics & Routes of Infusion

Half-Life: Ultra-short terminal half-life ( t 1 / 2 < 1 minute t_{1/2} < 1\text{ minute} t 1/2 ​ < 1 minute ) due to extensive first-pass metabolism ( 60% to 90% ) by 15-hydroxyprostaglandin dehydrogenase in the pulmonary vascular bed. Consequently, PGE1 must be delivered as a continuous intravenous infusion; any accidental line interruption results in acute ductal constriction within minutes.

Infusion Sites: PGE1 can be infused via a peripheral IV line, umbilical venous catheter (UVC), or central venous line. Umbilical artery catheters (UAC) placed with the tip at the ductus level have been utilized historically, but intravenous delivery is equally effective and carries lower thrombotic risk. Intra-arterial infusion must be avoided peripherally due to severe localized vasoconstriction/erythema.

Adverse Effect Profile & Proactive Management

Adverse Event Incidence Pathophysiology & Presentation Clinical Management & Board Pearls

Apnea 10% to 12% Direct central depression of brainstem respiratory drive; highest risk in preterm infants, neonates weighing < 2 kg < 2\text{ kg} < 2 kg , and during high initial doses ( > 0.05 mcg/kg/min > 0.05\text{ mcg/kg/min} > 0.05 mcg/kg/min ). Peak onset occurs within the first 1 to 2 hours of infusion initiation. Mandatory bedside intubation readiness : endotracheal tube, bag-valve-mask, functioning suction, and mechanical ventilator immediately available. Apnea is not an indication to discontinue PGE1 if the lesion is ductal dependent; initiate bag-mask ventilation or elective endotracheal intubation.

Hypotension & Peripheral Vasodilation 15% to 20% Systemic arterial and venous smooth muscle relaxation leading to venous pooling, warm shock, and widened pulse pressure. Volume expansion with 10 mL/kg 10\text{ mL/kg} 10 mL/kg isotonic crystalloid boluses; titrate PGE1 down to lowest effective maintenance dose ( 0.01 mcg/kg/min 0.01\text{ mcg/kg/min} 0.01 mcg/kg/min ); initiate vasopressors (e.g., dopamine, epinephrine) if vasoplegia persists.

Hyperpyrexia (Fever) 10% to 15% Prostaglandin-mediated elevation of hypothalamic thermal set point and peripheral cutaneous vasodilation. Self-limiting vasomotor phenomenon. Does not represent new-onset sepsis; avoid reflex escalations of empiric broad-spectrum antibiotics unless clinical signs of infection (leukocytosis, bandemia, hypothermia, hemodynamic collapse) are present.

Cutaneous Flushing 10% to 40% Superficial microvascular vasodilation; infant exhibits intense red blotchy erythema. Benign; reassurance and dose titration.

Cortical Hyperostosis High with prolonged use ( > 7 – 14 days > 7\text{--}14\text{ days} > 7 – 14 days ) Stimulation of osteoblasts in the periosteum of long bones, producing periosteal thickening, bone pain, and limb swelling. Monitor alkaline phosphatase and limb x-rays in infants receiving prolonged infusions; fully reversible weeks to months after PGE1 discontinuation.

Antral Foveolar Hyperplasia High with prolonged use ( > 2 – 4 weeks > 2\text{--}4\text{ weeks} > 2 – 4 weeks ) Mucosal smooth muscle and foveolar epithelial hypertrophy in the gastric pylorus, presenting as gastric outlet obstruction mimicking hypertrophic pyloric stenosis. Monitor gastric aspirates and feeding intolerance; perform abdominal ultrasound if non-bilious projectile emesis develops. Reversible upon cessation.

Hypokalemia & Platelet Dysfunction Variable Renal tubular kaliuresis; mild inhibition of platelet aggregation. Monitor serum electrolytes every 24–48 hours; replate potassium to maintain > 4.0 mEq/L > 4.0\text{ mEq/L} > 4.0 mEq/L .

Warning

In Ductal-Dependent Systemic Lesions (e.g., HLHS): Excessive Oxygen is Toxic. High concentrations of supplemental oxygen act as a potent pulmonary vasodilator while mildly constricting ductal tissue. In an infant with HLHS, lowering PVR causes massive pulmonary overcirculation at the expense of systemic perfusion ("pulmonary steal"), precipitating profound cardiogenic shock and metabolic acidosis. In ductal-dependent systemic lesions, maintain ambient oxygen or target mild sub-ambient therapy to achieve target S p O 2 SpO_2 Sp O 2 ​ of 75% to 85% and a balanced Q p : Q s Q_p:Q_s Q p ​ : Q s ​ ratio of 1:1.

Single-Ventricle Staged Palliation Pathways

Infants born with single-ventricle physiology—most notably Hypoplastic Left Heart Syndrome (HLHS) , double-inlet left ventricle, or severe tricuspid atresia—cannot undergo biventricular anatomical repair. Instead, they undergo a staged three-step surgical palliation pathway designed to divert systemic venous blood passively into the pulmonary arterial bed, dedicating the single morphologic ventricle exclusively to driving systemic circulation. Single-Ventricle Surgical Staged Palliation Paradigm (HLHS Model)

  • Stage 1: Norwood / Sano (Neoaorta + Systemic-to-Pulmonary Shunt)
  • [Timing: First 1-2 Weeks of Life]
  • Connects RV to reconstructed neoaorta
  • Unrestricted atrial communication (atrial septectomy)
  • Pulmonary blood flow via mBT shunt or Sano conduit
  • High interstage mortality; Aspirin 1-5 mg/kg/day mandatory
  • │
  • ▼
  • Stage 2: Bidirectional Glenn (Superior Cavopulmonary Anastomosis)
  • [Timing: 4 - 6 Months of Age]
  • Shunt takedown; SVC anastomosed directly to Pulmonary Artery
  • Decompresses single ventricle (reduces volume overload)
  • In-line pulmonary blood flow from upper body
  • │
  • ▼
  • Stage 3: Fontan Completion (Total Cavopulmonary Connection)
  • [Timing: 2 - 4 Years of Age (Weight ~12-15 kg)]
  • IVC flow redirected to Pulmonary Artery (extracardiac conduit)
  • Completely separates oxygenated and deoxygenated circuits
  • Entire pulmonary blood flow is passive (non-pulsatile, no subpulmonary pump)
  • High lifelong risk of thrombosis, PLE, and plastic bronchitis
  • Stage 1: Norwood Procedure (with mBT Shunt or Sano Conduit)

Timing: Performed within the first 1 to 2 weeks of life .

Surgical Components:

The diminutive native aorta and main pulmonary trunk are joined to construct a large neoaorta , allowing the right ventricle to pump blood unobstructed into the systemic and coronary circulations.

An atrial septectomy is performed to ensure unobstructed pulmonary venous return into the single ventricle.

Controlled pulmonary blood flow is established using either:

Modified Blalock-Taussig (mBT) Shunt: A synthetic polytetrafluoroethylene (PTFE) Gore-Tex tube (typically 3.0 to 3.5 mm diameter) placed between the right subclavian artery and the right pulmonary artery (systemic-to-pulmonary shunt).

Sano Shunt (RV-to-PA Conduit): A PTFE conduit connecting the right ventricle directly to the pulmonary artery bifurcation. The Sano shunt avoids the diastolic run-off (coronary steal) associated with the mBT shunt.

Stage 2: Bidirectional Glenn Procedure

Timing: Performed at 4 to 6 months of age , once pulmonary vascular resistance has reached physiological nadir.

Surgical Components: The mBT shunt or Sano conduit is taken down, and the superior vena cava (SVC) is anastomosed end-to-side directly onto the right pulmonary artery. Venous blood from the head and upper extremities flows passively into both lungs. This offloads volume burden from the single ventricle.

Stage 3: Fontan Procedure (Total Cavopulmonary Connection)

Timing: Performed at 2 to 4 years of age (patient weight typically 12 to 15 kg).

Surgical Components: The inferior vena cava (IVC) blood is routed directly into the pulmonary artery, typically via a prosthetic extracardiac conduit (or intra-atrial lateral tunnel). A small fenestration (4 to 5 mm hole) is often created between the conduit and the common atrium to act as a pop-off valve during periods of acute pulmonary pressure spikes, preserving cardiac output at the expense of mild cyanosis.

Physiology: Following the Fontan, both SVC and IVC blood flows passively through the pulmonary vascular bed without any subpulmonary pumping chamber. Central venous pressure (CVP) equals pulmonary arterial pressure (typically 12 to 16 mmHg).

Antithrombotic Management Across Palliation Stages

Children with single-ventricle physiology exist in an abnormal, prothrombotic hemodynamic environment characterized by synthetic prosthetic grafts, sluggish low-shear venous flow, polycythemia secondary to chronic hypoxemia, endothelial dysfunction, and progressive hepatic congestion.

Stage 1 (Interstage) Antithrombotic Management

The Risk: Acute mBT shunt thrombosis is a devastating, sudden event with mortality exceeding 50% . Platelet activation across the small-caliber (3.0–3.5 mm) synthetic PTFE graft lumen triggers platelet-rich white thrombi.

Standard Prophylaxis: Low-dose aspirin ( 1 to 5 mg/kg/day 1\text{ to }5\text{ mg/kg/day} 1 to 5 mg/kg/day , typically administered as 20.25 to 40.5 mg 20.25\text{ to }40.5\text{ mg} 20.25 to 40.5 mg once daily or 81 mg 81\text{ mg} 81 mg once daily in older infants) is the standard of care recommended by the American Heart Association (AHA) and Pediatric Heart Network trials.

Aspirin Resistance & Escalation: In infants exhibiting shunt stenosis or high clinical suspicion of aspirin failure, clopidogrel ( 0.2 mg/kg/day 0.2\text{ mg/kg/day} 0.2 mg/kg/day , titrating to platelet inhibition targets) may be added or substituted. Prophylactic enoxaparin ( 0.5 mg/kg/dose 0.5\text{ mg/kg/dose} 0.5 mg/kg/dose subQ every 12 hours targeting anti-Xa 0.2 – 0.4 units/mL 0.2\text{--}0.4\text{ units/mL} 0.2 – 0.4 units/mL ) is utilized in high-risk postoperative intervals.

Glenn & Fontan Anticoagulation Strategies

In the Fontan circulation, sluggish non-pulsatile venous flow, atrial dilation, and high rates of protein-losing enteropathy (PLE) —which causes catastrophic enteric loss of endogenous anticoagulants ( antithrombin III, protein C, and protein S )—produce a cumulative lifetime thromboembolism risk of 10% to 33% .

Standard Thromboprophylaxis: Long-term aspirin ( 81 mg/day 81\text{ mg/day} 81 mg/day ) is standard in low-risk Fontan patients.

Full Anticoagulation Indications: Warfarin (target INR 2.0 to 3.0) or therapeutic enoxaparin is mandatory in patients with:

  • Persistent conduit fenestrations (risk of paradoxical systemic arterial embolic stroke)
  • History of previous thromboembolism
  • Atrial tachyarrhythmias (intra-atrial reentrant tachycardia [IART])
  • Evident intracardiac thrombus or severe ventricular dysfunction ( E F < 30 % EF < 30\% EF < 30% )

Direct Oral Anticoagulants (DOACs): The UNIVERSE trial and expanding pediatric evidence support rivaroxaban and apixaban for thromboprophylaxis in stable post-Fontan pediatric patients, providing predictable anticoagulation without routine INR monitoring.

Practice Pearls & BCPPS Exam Traps

Exam Trap 1: When an infant presents with suspected coarctation of the aorta or HLHS, never administer high concentrations of supplemental oxygen. Oxygen drops PVR, steals blood from the systemic circulation into the lungs, and precipitates severe anuria and cardiogenic shock. Maintain S p O 2 SpO_2 Sp O 2 ​ at 75% to 85%.

Exam Trap 2: Do not mistake PGE1-induced hyperpyrexia for systemic neonatal bacterial sepsis. While blood cultures should be obtained if sepsis is clinically plausible, an isolated temperature spike to 38.5°C within 2 hours of initiating PGE1 without hemodynamic decompensation is a well-known eicosanoid effect.

Board Rule: Always prepare for endotracheal intubation before initiating alprostadil. Apnea occurs in up to 12% of patients; lack of immediate airway readiness is considered a major patient safety violation on the BCPPS exam.